[Clinical evaluation of cefotiam in internal medicine].
Cefotiam (CTM) was administered to 52 patients with infectious disease associated with respiratory system, hematological malignancy, urinary system and other system. Good clinical responses were obtained in 38 out of 52 cases (73.1%). Neither objective and subjective side effects nor extreme abnormalities of laboratory tests were observed in these patients. It can be, therefore, concluded that CTM is 1 of the most useful drugs for infectious diseases in respiratory system, hematological malignancy, urinary system and other system.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015310:Cefotiam; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D015310:Cefotiam; D002439:Cefotaxime